◆英語タイトル:Nevro Corp (NVRO) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1605
◆発行会社(調査会社):
GlobalData
◆発行日:2020年4月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Nevro Corp (NVRO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Nevro Corp (Nevro) is a medical device company which focuses on providing novel products that advance the quality of life of people suffering from chronic pain. The company has developed Nevro Senza spinal cord stimulation (SCS) system, a non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Nevro Senza SCS system is commercially available in the US, Europe and Australia. The company offers products under Senza, Senza II and the Nevro logo brands. Nevro is developing HF10 therapy for treating painful diabetic neuropathy and non-surgical refractory back pain. Nevro is headquartered in Redwood City, California, the US.
Nevro Corp Key Recent Developments
Apr 01,2020 Nevro provides first quarter and FY2020 update
Jan 20,2020 Nevro names Donald A. Middlebrook to lead clinical, regulatory and quality
Jan 14,2020 Nevro announces preliminary unaudited fourth quarter and full year 2019 revenue
Dec 18,2019 Nevro appoints Karen N. Prange to the company’s board of directors
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Nevro Corp – Key Facts
Nevro Corp – Key Employees
Nevro Corp – Key Employee Biographies
Nevro Corp – Major Products and Services
Nevro Corp – History
Nevro Corp – Company Statement
Nevro Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Nevro Corp – Business Description
Geographical Segment: International
Target Markets
Performance
Geographical Segment: United States
Performance
R&D Overview
Nevro Corp – Corporate Strategy
Nevro Corp – SWOT Analysis
SWOT Analysis – Overview
Nevro Corp – Strengths
Nevro Corp – Weaknesses
Nevro Corp – Opportunities
Nevro Corp – Threats
Nevro Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Nevro Corp, Medical Equipment, Deals By Year, 2014 to YTD 2020
Nevro Corp, Medical Equipment, Deals By Type, 2014 to YTD 2020
Nevro Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 01, 2020: Nevro provides first quarter and FY2020 update
Jan 20, 2020: Nevro names Donald A. Middlebrook to lead clinical, regulatory and quality
Jan 14, 2020: Nevro announces preliminary unaudited fourth quarter and full year 2019 revenue
Dec 18, 2019: Nevro appoints Karen N. Prange to the company’s board of directors
Nov 06, 2019: Nevro reports third quarter 2019 financial results
Aug 08, 2019: Nevro reports second quarter 2019 financial results
Jun 25, 2019: Nevro announces executive appointments
May 20, 2019: Nevro appoints D. Keith Grossman Chairman of the Board; Michael DeMane as Lead Director
May 09, 2019: Nevro reports first quarter 2019 financial results
Mar 19, 2019: Nevro announces new CEO, board appointments and agreement with Broadfin Capital
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Nevro Corp, Key Facts
Nevro Corp, Key Employees
Nevro Corp, Key Employee Biographies
Nevro Corp, Major Products and Services
Nevro Corp, History
Nevro Corp, Subsidiaries
Nevro Corp, Key Competitors
Nevro Corp, Ratios based on current share price
Nevro Corp, Annual Ratios
Nevro Corp, Annual Ratios (Cont...1)
Nevro Corp, Interim Ratios
Nevro Corp, Medical Equipment, Deals By Year, 2014 to YTD 2020
Nevro Corp, Medical Equipment, Deals By Type, 2014 to YTD 2020
Nevro Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Nevro Corp, Performance Chart (2015 - 2019)
Nevro Corp, Ratio Charts
Nevro Corp, Medical Equipment, Deals By Year, 2014 to YTD 2020
Nevro Corp, Medical Equipment, Deals by Type, 2014 to YTD 2020